Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: Four open-label, randomized, crossover studies in healthy adults

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 7, 2008, Pages 382-395

  Eklund, Annika ^a   Tronde, Ann ^a   Johannes Hellberg, Ingegerd ^a   Gillen, Michael ^b   Borgström, Lars ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bioavailability; Budesonide; Budesonide formoterol pMDI; Combination inhaler; Formoterol; Pharmacokinetics; Symbicort

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; OXIS TURBUHALER; SYMBICORT TURBUHALER; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MONOTHERAPY; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; STEADY STATE; TREMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED; NEBULIZER; PARTICLE SIZE;

ADULT; AREA UNDER CURVE; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; METERED DOSE INHALERS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 56149087093     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.622     Document Type: Article

References (35)

1. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics - 2002. J Allergy Clin Immunol 2002; 110: S141-S219.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2006 Update. Available at: http://www.ginasthma.com/Guidelineitem.asp?l1=2&l2=1&intId=60.
3. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2005 Update. Available at: http://www.goldcopd.com/ download.asp?intID=234.
4. Stoloff SW, Stempel DA, Meyer J, Stanford JH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113: 245-251. doi:10.1016/ j.jaci.2003.10.011
5. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol 1997; 79: 177-186.
6. Buhl R, Creemers JPHM, Vondra V, Martelli NA, Naya IP, Ekström T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003; 97: 323-330.
7. Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123: 1480-1487. doi:10.1378/chest.123.5.1480
8. Tal A, Simon G, Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34: 342-350. doi:10.1002/ ppul.10173
9. Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262-268.
10. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003; 16: 147-151.
11. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
12. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
13. Donnelly R, Seale JP. Clinical pharmacokinetics of inhaled budesonide. Clin Pharmacokinet 2001; 40: 427-440. doi:10.2165/ 00003088-200140060-00004
14. Kaiser H, Aaronson D, Dockhorn R, Edsbäcker S, Korenblat P, Källén A. Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler®. Br J Clin Pharmacol 1999; 48: 309-316. doi:10.1046/j.1365-2125.1999.00008.x
15. Minto C, Li B, Tattam B, Brown K, Seale JP, Donnelly R. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation - intersubject variability in systemic absorption from the lung. Br J Clin Pharmacol 2000; 50: 116-124. doi:10.1046/ j.1365-2125.2000.00218.x
16. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child 1999; 80: 241-247.
17. Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer™. Eur J Clin Pharmacol 1999; 55: 131-138. doi:10.1007/s002280050607
18. Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55: 303-322. doi:10.2165/ 00003495-199855020-00016
19. Thorsson L, Edsbäcker S, Källén A, Löfdahl C-G. Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®. Br J Clin Pharmacol 2001; 52: 529-538. doi:10.1046/j.0306-5251.2001.01493.x
20. Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64: 1597-1618. doi:10.2165/ 00003495-200464140-00006
21. 2-agonists in the management of obstructive pulmonary disease. Drug Safety 2004; 27: 689-715. doi:10.2165/00002018-200427100-00001
22. Gulliver T, Eid N. Effects of glucocorticoids on the hypothalamic-pituitary-adrenal axis in children and adults. Immunol Allergy Clin North Am 2005; 25: 541-555, vii. doi:10.1016/ j.iac.2005.04.001
23. Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16-33. doi:10.1034/j.1398-9995.2000.00370.x
24. Newman SP. Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 2003; 42: 529-544. doi:10.2165/ 00003088-200342060-00003
25. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005; 50: 367-382.
26. Banov CH. The role of budesonide in adults and children with mild-to-moderate persistent asthma. J Asthma 2004; 41: 5-17. doi:10.1081/JAS-120026092
27. Brogden RN, McTavish D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44: 375-407.
28. Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 97: 24-33.
29. Cazzola M, Santus P, Di Marco F, et al. Onset of action of formoterol/budesonide in single inhaler vs formoterol in patients with COPD. Pulm Pharmacol Ther 2004; 17: 121-125.
30. Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781-791. doi:10.1007/s002280000233
31. Houghton CM, Langley SJ, Singh SD, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 2004; 58: 359-366. doi:10.1111/ j.1365-2125.2004.02172.x
32. 3H]formoterol in healthy men after combined i.v. and oral administration - mimicking inhalation. Drug Metab Dispos 1999; 27: 1104-1116.
33. Borgström L. In vitro, ex vivo, in vivo veritas. Allergy 1999; 54: 88-92.
34. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1: 171-175. doi:10.1513/pats.200402-016MS
35. Foradil® Aerolizer® (Formoterol Fumarate Inhalation Powder) Prescribing Information. Novartis Pharma AG: Basel, Switzerland, October 2002.